- Conditions
- Preterm Birth
- Interventions
- 17-Hydroxyprogesterone caproate 250mg or 500 mg., Safety study of 500 mg dose.
- Drug
- Lead sponsor
- Steve N. Caritis, MD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Preterm Birth
- Interventions
- 17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-Hydroxyprogesterone Caproate 275 mg SC Dose
- Drug
- Lead sponsor
- Steve N. Caritis, MD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Newark, Delaware • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
- Conditions
- Opiate Addiction, Pregnancy
- Interventions
- Magnitude Group, Frequency Group
- Drug
- Lead sponsor
- Steve N. Caritis, MD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Knoxville, Tennessee